

<b>Roxane Tenta, M.Sc., Ph.D</b>		POSITION TITLE <b>Lecturer in Human Physiology</b> Department of Nutrition Science-Dietetics, Harokopio University, El.Venizelou 70, 17671, Athens, Greece Tel: 00302109549153, e-mail: rtenta@hua.gr	
<b>EDUCATION / TRAINING</b>			
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
School of Pharmacy, University of Athens, Greece	B.Sc.	1994 - 1999	Bachelor of Pharmacy
University Pierre et Marie Curie (Paris VI), Paris, France	M.Sc. (D.E.A de Pharmacologie Moléculaire et Cellulaire)	1999 - 2000	Master degree in Cellular and Molecular Pharmacology (option: Oncology)
Department of Experimental Physiology, Medical School-University of Athens.	Ph.D.	2001 - 2004	Thesis: "Role of PTHrP and of PTH/PTHrP receptor in the pathophysiology of prostate cancer cells".
Department of Experimental Physiology, Medical School-University of Athens.	Post-doc	2005-2006	Research project: "Microarray analysis of survival pathways in human PC-3 prostate cancer cells".

## Languages

English: "Certificate of Proficiency in English" - University of Cambridge

French: "Diplôme d' Etudes Françaises" - 2<sup>E</sup> Degré - Université de Paris, Sorbonne (Paris IV)

German: "Kleines Deutsches Sprachdiplom" (KDS) - Goethe Institut

Spanish: "Diploma Intermedio de Espanol" - Instituto Cervantes

## Positions and Employment

2007-Present	Lecturer in Human Physiology at the Department of Nutrition & Dietetics, Harokopio University
2004- 2007	Research & Teaching Associate at the Department of Nutrition & Dietetics, Harokopio University
2003- 2006	Subinvestigator in the International Clinical Trial (Clinical Protocol No CZOL 446GGR01/3 JULY 2002), K.A. 70/3/6883 under the approval of The National Drug Federation.
1999-2000	Research position in Institut de Recherches Servier - Oncology Department, Paris, France.

## Honors and Awards - Grants

1999-2000	Scholarship from the Asimakopoulos Institution for graduate studies - master degree- D.E.A (Pharmacologie Moléculaire et Cellulaire) in the University Pierre et Marie Curie (Paris VI)
2004	Scholarship from the Alexander S. Onassis Institution for the attendance at the Series of Lectures on "Genomics, Bioinformatics and beyond", organized in cooperation with the Foundation for Research and Technology-Hellas (FORTH), Heraklion, Crete
2005-2006	Scholarship of the Ministry of Education "PYTHAGORAS II" post-doctoral award program
2006	Scholarship from the European Commission Marie Curie Actions Programme, for the attendance at the 14th Euroconference on Apoptosis and at the 'Concepts and Methods in Programmed Cell Death', organized in Sardegna, Italy
2006	Scholarship from the European Commission Marie Curie Actions Programme, for the attendance at the 1st Workshop on the Immune response against dying tumor cell, organized in Villejuif, France.
2006	33 <sup>rd</sup> Panhellenic Congress on Endocrinology and Metabolism, Athens (29-31/3/2006). Best Poster Award "PPAR $\gamma$ ligand-mediated cytotoxic and cytostatic effect of doxorubicin in PC-3 prostate cancer cells". Papageorgiou E, Pitulis N, Tenta R, Kletsas D, Manoussakis M, Koutsilieris M.
2009	Latsis Foundation – Grant for the Study of unique Greek varieties plant extracts and evaluation of their potent use as drugs against osteoporosis.

## Participation in Congresses

29 abstracts in international congresses and 32 abstracts in national congresses

## Publications

1. Osteoprotegerin and nuclear factor-kappaB ligand are associated with leptin and adiponectin levels, in apparently healthy women. R.Tenta, D.B.Panagiotakos, E.Fragopoulou, T.Nomikos, C.Pitsavos, C.Chrysohoou, S. Antonopoulou, C.Stefanadis. *J Musculoskelet Neuronal Interact.(JMNI)* 2010; 10 (2):174-9.
2. Activation of AMP-activated protein kinase by adiponectin rescues salivary gland epithelial cells from spontaneous and interferon-gamma-induced apoptosis. Katsiogiannis S, Tenta R, Skopouli FN. *Arthritis Rheum.* 2010 Jan 7;62(2):414-419.
3. MG-63 osteoblast-like cells enhance the osteoprotegerin expression of PC-3 prostate cancer cells. Katopodis H, Philippou A, Tenta R, Doillon C, Papachroni KK, Papavassiliou AG, Koutsilieris M. *Anticancer Res.* 2009 Oct;29(10):4013-8.
4. Comparison of two schemes of small bowel preparation for capsule endoscopy with polyethylene glycol: a prospective, randomized single-blind study. Kantianis A, Karagiannis S, Liatsos C, Galanis P, Psilopoulos D, Tenta R, Kalantzis N, Mavrogiannis C. *Eur J Gastroenterol Hepatol.* 2009 Oct;21(10):1140-4.
5. IL-6 and PPAR[gamma] Signalling in Human PC-3 Prostate Cancer Cells. Pitulis N, Papageorgiou E, Tenta R, Lembessis P, Koutsilieris M. *Anticancer Res.* 2009 Jun;29(6):2331-7.
6. The Application of Mitsunobu Cyclization for the Synthesis of 2',3'-Dideoxy-C-Nucleosides Designed as Didanosine Analogues. Tony Tite, Nikolaos Lougiakis,Alexios-Leandros Skaltsounis, Panagiotis Marakos, Nicole Pouli, Roxane Tenta, Jan Balzarini. *Synlett* 2009 (11): 1741-1744.
7. Mechanisms of the Action of Zoledronic Acid on Human MG-63 Osteosarcoma Cells. Tenta R, Pitulis N, Tiblalex D, Consoulas C, Katopodis H, Konstantinidou E, Manoussakis M, Kletsas D, Alexis MN, Poyatzi A, Koutsilieris M.*Horm Metab Res.* 2008 Nov;40(11):737-45.
8. Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Tenta R, Katopodis H, Chatziioannou A, Pilalis E, Calvo E, Luu-The V, Labrie F, Kolisis F, Koutsilieris M. *Cancer Genomics Proteomics.* 2007 Jul-Aug;4(4):309-18.
9. Analgesic activity of high-dose intravenous calcitonin in cancer patients with bone metastases. Tsavaris N, Kopterides P, Kosmas C, Vadiaka M, Dimitrakopoulos A, Scopelitis H, Tenta R, Vaiopoulos G, Koufos C. *Oncol Rep.* 2006 Oct;16(4):871-5.
10. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. M.Koutsilieris, J.Bogdanos, C.Milathianakis, P.Dimopoulos, T.Dimopoulos, D.Karamanolakis, A.Halapas, R.Tenta, H.Katopodis, E.Papageorgiou, N.Pitulis, N.Pissimissis, P.Lembessis and A. Sourla *Expert Opin Investig Drugs.* 2006 Jul;15(7):795-804.
11. Bone microenvironment-related growth factors and zoledronic acid regulate PTHrP / PTH.1 Receptor bioregulation system in MG-63 human osteosarcoma cells. Roxane Tenta, Antigone Sourla, Peter Lembessis and Michael Koutsilieris. *Anticancer Res* 2006; 26: 283-292.

12. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone modulate differentially the PTHrP expression in PC-3 prostate cancer cells. Roxane Tenta, Antigone Sourla, Peter Lembessis, Van Luu-The and Michael Koutsilieris. *Horm Metab Res* 2005; 37: 593-601.
13. Design, synthesis and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cells. Kostakis IK, Tenta R, Pouli N, Marakos P, Skaltsounis AL, Pratsinis H, Kletsas D. *Bioorg Med Chem Lett*. 2005; 15; 5057-5060.
14. p27<sup>kip1</sup> and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. Kyriakos Revelos, Constantina Petraki, Alkiviadis Gregorakis, Andreas Scorilas, Panagiotis Papanastasiou, Roxane Tenta and Michael Koutsilieris. *In Vivo*, 2005; 19: 911-920.
15. Prostate cancer cell survival pathways activated by bone metastasis microenvironment. Tenta R, Sotiriou E, Pitulis N, Thyronitis G, Koutsilieris M. *JMNI (Journal of Musculoskeletal and Neuronal Interactions)*, 2005; 5: 135-144.
16. Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Tenta R, Tiblalexid D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M. *Prostate*, 2004; 59: 120-131.
17. Parathyroid hormone-related peptide and cardiovascular system. Halapas A, Tenta R, Pantos C, Cokkinos DV, Koutsilieris M. *In Vivo*, 2003 Sep-Oct; 17 (5): 425-432.
18. Endocrine / Paracrine / Autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Bogdanos J, Karamanolakis D, Tenta R, Tsintavis A, Milathianakis C, Mitsiades C, Koutsilieris M. *Endocr-Relat Cancer*, 2003 Jun; 10(2): 279-289.
19. Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement. Karamanolakis D, Bogdanos J, Sourla A, Milathianakis C, Tsintavis A, Lembessis P, Tenta R, Tiblalexid D, Koutsilieris M. *Mol Med*. 2002 Nov; 8 (11): 667-75.